Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2119 • ACR Convergence 2022
Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naïve or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
M. Elaine Husni¹, Philip J Mease², Joseph Merola³, Frank Behrens⁴, Ennio Giulio Favalli⁵, Dennis McGonagle⁶, William Tillett⁷, Shigeyoshi Tsuji⁸, Barbara Ink⁹, Deepak Assudani⁹, Rajan Bajracharya⁹, Jason Coarse¹⁰, Jérémy Lambert¹¹ and Laure Gossec¹², ¹Cleveland Clinic, Cleveland, OH, ²Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ³Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁵University of Milan, ASST Gaetano Pini-CTO Institute, Milano, Italy, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸Department of Orthopaedics and Rheumatology, Nippon Life Hospital, Osaka, Japan, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹¹UCB Pharma, Colombes, France, Irigny, France, ¹²Sorbonne Université, Paris, France
Background/Purpose: Patients with psoriatic arthritis (PsA) have identified fatigue and pain as important features relevant to their burden of disease.1 Bimekizumab (BKZ), a monoclonal IgG1…
Abstract Number: 2136 • ACR Convergence 2022
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis: Achievement of Minimal Disease Activity and Its Components
Arthur Kavanaugh¹, Laura Coates², Joseph Merola³, Philip J Mease⁴, Miroslawa Nowak⁵, Subhashis Banerjee⁵, Lauren Hippeli⁵ and Tom Lehman⁵, ¹University of California San Diego, La Jolla, CA, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁵Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase in the Janus kinase (JAK) family that mediates the signaling of multiple cytokines, including those central…
Abstract Number: 2153 • ACR Convergence 2022
Key Differences Between US Rheumatologists’ and Dermatologists’ Management of Psoriatic Arthritis
Maxine Yarnall, Spherix Global Insights, Exton, PA
Background/Purpose: The last few years have seen the approval of many new agents for the treatment of psoriatic arthritis (PsA) and psoriasis (PSO), resulting in…
Abstract Number: 0377 • ACR Convergence 2022
Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies
Maria Angeles Puche Larrubia¹, lourdes Ladehesa-Pineda², María Dolores López Montilla², Raquel Granados³, Eduardo Collantes⁴ and Clementina Lopez-Medina⁵, ¹Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Granada, Spain, ²Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, ³Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, ⁴IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ⁵Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain
Background/Purpose: The prevalence of late-onset Psoriatic Arthritis (PsA) is increasing in parallel with the progressive aging of the population. The elderly population presents a greater…
Abstract Number: 0699 • ACR Convergence 2022
Effectiveness by Disease Severity in Patients with Psoriatic Arthritis Treated with Apremilast in the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Alexis Ogdie¹, Jacqueline O'Brien², Wendi Malley², Elizabeth Kohl², Kate Orroth³, Yuri Klyachkin⁴, Myriam Cordey⁵ and Philip J Mease⁶, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³Amgen, Manhattan Beach, CA, ⁴Amgen, Lexington, KY, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Clinical trials of the efficacy and safety of apremilast have shown a significant therapeutic effect on disease activity across clinically diverse PsA patients. Given…
Abstract Number: 1021 • ACR Convergence 2022
Depression as a Modulator of Patient Reported, but Not Physician Observed, Outcomes in Psoriatic Arthritis
Rebecca Haberman¹, Seungha Um², Sydney Catron¹, Eileen Lydon³, Malavika Attur², Andrea Neimann², Soumya Reddy⁴, Andrea Troxel¹, Samrachana Adhikari¹ and Jose Scher⁵, ¹NYU Langone Health, New York, NY, ²NYU Langone, New York, NY, ³New York University, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a complex immune-mediated disease. Beyond its deleterious effects in the skin and joints, PsA can lead to decreased quality of…
Abstract Number: 1096 • ACR Convergence 2022
IL-23 Induced Growth Differentiation Factor 15 Contributes to Trabecular Bone Loss, but Does Not Affect Skin, Gut or Joint Inflammation in Psoriatic Arthritis
Renée Van der Cruyssen¹, Djoere Gaublomme¹, Emilie Dumas¹, Carolien Vlieghe¹, Flore Stappers², Julie Coudenys¹, Tine Decruy¹, Lars Vereecke¹, Eric Gracey¹ and Dirk Elewaut³, ¹VIB-UGent Center for Inflammation Research, Ghent University, Belgium, Gent, Belgium, ²VIB-UGent Center for Inflammation Research, Ghent University, Ghent, Belgium, ³Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium
Background/Purpose: IL-23 mediated inflammatory diseases such as psoriasis and psoriatic arthritis are associated with bone loss in addition to more classical features such as skin…
Abstract Number: 1425 • ACR Convergence 2022
Treatment Persistence and Switching Patterns of ABP 501 (AMGEVITA®) in German Patients with Rheumatic Diseases
Ran Jin¹, Silvia Kruppert², Florian Scholz², Marc Hammer², Greg Kricorian¹, David Collier³ and Jonathan Kay⁴, ¹Amgen, Inc., Thousand Oaks, CA, ²IQVIA, Frankfurt, Germany, ³Amgen Inc., Simi Valley, CA, ⁴Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA
Background/Purpose: ABP 501 is the first adalimumab (ADA) biosimilar approved by the European Medical Association and the Food and Drug Administration for the treatment of…
Abstract Number: 1506 • ACR Convergence 2022
Multimorbidity in Psoriasis as a Risk Factor for Psoriatic Arthritis: A Population-Based Study
Paras Karmacharya¹, Rikesh Chakradhar², Alexis Ogdie³, John Davis⁴, Tina Gunderson⁴, Cassondra Hulshizer⁴, Kerry Wright⁴, Megha M. Tollefson⁵, Ali Duarte-Garcia⁴, Delamo Bekele⁴, Hilal Maradit Kremers⁴, Floranne Ernste⁴ and Cynthia Crowson⁶, ¹Vanderbilt University, Nashville, TN, ²St. Christopher's Hospital, Philadelphia, ³Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Rochester, ⁶Mayo Clinic, Eyota, MN
Background/Purpose: Psoriasis is a systemic inflammatory disorder associated with cardiometabolic and other comorbidities. Psoriasis frequently precedes development of psoriatic arthritis (PsA), and comorbidities in psoriasis…
Abstract Number: 1768 • ACR Convergence 2022
Sex-Related Differences in Healthcare Utilization in Patients with Inflammatory Arthritis: A Population-based Study
Sanjana Tarannum¹, Jessica Widdifield¹, C. Fangyun Wang², Sindhu R. Johnson³, Paula Rochon¹ and Lihi Eder⁴, ¹University of Toronto, Toronto, ON, Canada, ²Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ³Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Delayed diagnosis of inflammatory arthritis (IA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA), is associated with joint damage and disability.…
Abstract Number: 2120 • ACR Convergence 2022
Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of 11 Phase 2/3 Clinical Studies in Psoriasis and Psoriatic Arthritis
Bruce Strober¹, Laura Coates², Jenny Yu³, Katelyn Rowland⁴, Evan Leibowitz⁴, Megan Miller⁵, Alexa Kollmeier⁶, Shu Li⁵, Yanli Wang⁵, Daphne Chan⁴, Soumya Chakravarty⁷, Ya-Wen Yang⁸, May Shawi⁸, Mark Lebwohl⁹ and Proton Rahman¹⁰, ¹Yale University, New Haven, CT; Central Connecticut Dermatology Research, Cromwell, CT, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Janssen Research & Development, LLC, Spring House, PA/San Diego, CA, USA, San Diego, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Research & Development, LLC, Spring House, PA/San Diego, Spring House, PA/San Diego, CA, ⁶Janssen-Cilag, Research & Development, LLC, San Diego, CA, ⁷Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁸Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁹Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰Memorial University, St. John's, NL, Canada
Background/Purpose: Guselkumab (GUS) is a fully human monoclonal antibody that selectively binds to the p19 subunit of interleukin-23, inhibiting its function. GUS has been shown…
Abstract Number: 2137 • ACR Convergence 2022
Impact of Patient Characteristics, Including Sex, on the Efficacy of Upadacitinib Compared with Adalimumab in Patients with Psoriatic Arthritis
Lihi Eder¹, Laura Coates², Peter Nash³, Uta Kiltz⁴, Ennio Lubrano⁵, Erin McDearmon-Blondell⁶, Tianming Gao⁷ and Alexis Ogdie⁸, ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³School of Medicine, Griffith University, Brisbane, Australia, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ‘‘Vincenzo Tiberio’’, Università degli Studi del Molise, Campobasso, Italy, ⁶AbbVie, Inc., Mettawa, IL, ⁷AbbVie, Inc., North Chicago, IL, ⁸Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Evidence suggests that response to treatment in PsA may vary with patient (pt) characteristics, such as sex.1 This post hoc analysis of the Phase…
Abstract Number: 2199 • ACR Convergence 2022
Primary Non-adherence to Biologics and Immunomodulatory Therapies for Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis Using Linked EHR and Pharmacy Claims Data
Jeffrey Curtis¹, Yujie Su², Cassie Clinton², Patrick Stewart³, Bryant England⁴, Tim Buekelman⁵ and Fenglong Xie², ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Bendcare, Boca Raton, FL, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵FASTER, Hoover, AL
Background/Purpose: Many patients with autoimmune and inflammatory conditions discontinue biologics and other immunomodulatory medications prematurely, but many fail to even start (primary non-adherence). We examined…
Abstract Number: 0380 • ACR Convergence 2022
Changes in Disease Activity and Patient-Reported Outcomes in Psoriatic Arthritis Patients Treated with Ixekizumab in a Real-World US Cohort
William Tillett¹, Julie Birt², Cristi Cavanaugh³, Yoojin Jung³, Aisha Vadhariya², Sarah Ross², Jessica Paulus³, Aubrey Sprabery² and Ennio Lubrano⁴, ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Eli Lilly and Company, Indianapolis, IN, ³OM1, Inc., Boston, MA, ⁴Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ‘‘Vincenzo Tiberio’’, Università degli Studi del Molise, Campobasso, Italy
Background/Purpose: Ixekizumab (IXE), an IL-17A inhibitor, has demonstrated efficacy in clinical trials1-3 but real-world effectiveness data are limited.4 This study describes changes in disease activity…
Abstract Number: 0722 • ACR Convergence 2022
Cardiovascular and Oncologic Outocomes of Anti-TNF Alfa and JAK Inhibitors in Patients with Rheumatoid and Psoriatic Arthritis. Real World Data and Insights of BIOBADASAR 3.0 Registry
Alejandro Brigante¹, Rosana Quintana², Carolina Isnardi³, Karen Roberts⁴, Gimena Gomez⁵, Maria Haye Salinas⁶, Enrique Soriano⁷, Guillermo Pons-Estel⁸, Maria De la Vega⁸, Osvaldo kerzberg⁷, Julieta Gamba⁷, Anastasia Secco⁹, Gustavo Citera¹⁰, Cesar Graf⁷, Veronica Savio¹¹, Maria de los Angeles Gallardo⁷, Nora Aste⁷, Mercedes A Garcia¹², Gustavo Casado⁷, Carla Gobbi⁷, Graciela Gomez⁷, Joan Manuel Dapeña¹³, Guillermo Berbotto⁷, Malena Viola⁷, Jonathan Rebak⁷, Diana Dubinsky⁷, Veronica Saurit¹⁴, Ingrid Petkovic⁷, Ana Bertoli⁷, Erika Catay⁷, C Leoni⁷, Ida Elena Exeni⁷, Bernardo Pons-Estel¹⁵, Sergio Paira⁷, GH Bovea Castelblanco⁷, Mercedes De la Sota⁷, Dora Pereira⁷, Gustavo Medina⁷, Amelia Granel⁷, Maria s Larroude⁷, Analia Patricia Alvarez⁷, Santiago Agüero¹⁶, Cecilia Pisoni¹⁷, Monica Sacnun⁷ and Edson Velozo¹⁸, ¹UNISAR, Lobos, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas. Grupo Oroño (GO CREAR) and Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, ³SAR-COVID Coordinator, Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, ⁴UNISAR, Rosario, Argentina, ⁵Sanatorio Guemes, Buenos Aires, Argentina, ⁶UNLAR, La Rioja, Argentina, ⁷On behalf of the BIOBADASAR 3.0 registry, Buenos Aires, Argentina, ⁸Argentine Society of Rheumatology, Buenos Aires, Argentina, ⁹Rivadavia Hospital, Buenos Aires, Argentina, ¹⁰Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina, ¹¹Hospital Córdoba; Consultora Integral de Salud CMP, Cordoba, Argentina, ¹²HIGA San Martin, La Plata, Argentina, ¹³Hospital General de Agudos Dr. Enrique Tornu, Buenos Aires, Argentina, ¹⁴Hospital Privado Universitario, Cordoba, Argentina, ¹⁵Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ¹⁶Centro de Rehabilitación Dr Mauricio Figueroa, Catamarca, Argentina, ¹⁷CEMIC- Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina, ¹⁸SAR COVID Investigator, Caba
Background/Purpose: Major adverse cardiovascular events (MACE) and neoplasms are a concern in autoimmune diseases. RA and PsA are diseases where inflammation plays a key role…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].